Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03008239
Other study ID # P-4.5-C-01
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date November 14, 2017
Est. completion date October 2019

Study information

Verified date September 2019
Source Lee's Pharmaceutical Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the performance and safety of the fluorescence based fibre optic glucose sensor for home usage.24 subjects will take part in the study, including 4 pre-diabetic subjects, 8 Type I diabetic patients, 8 Type II diabetic patients and 4 diabetic patients who require continuous ambulatory peritoneal dialysis (CAPD). Type 1, Type 2 and prediabetic subjects will wear one FiberSense sensor, randomly allocated to either the upper arm (50%) or abdomen (50%) for 28 days. In addition, these subjects will wear a Dexcom sensor on the other side of the abdomen for 7 days in one of the four study weeks. In all 4 CAPD subjects, one FiberSense sensor will be placed in the upper arm for 28 days. No additional comparator sensor will be placed in CAPD subjects.


Description:

The FiberSense system is a glucose-monitoring device indicated for continually recording interstitial fluid glucose levels in patients ages 18 and older with insulin dependent diabetes mellitus for the purpose of improving diabetes management. The System is intended for use by patients at home and in health care facilities.

The FiberSense system is indicated for use as an adjunctive device to complement, not replace, information obtained from standard home glucose monitoring devices.

The FiberSense system aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments, which may minimize these excursions.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 26
Est. completion date October 2019
Est. primary completion date July 10, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Type I or II diabetes mellitus requiring insulin in the management of glucose control for at least one year prior to enrollment or diabetes on continuous ambulatory peritoneal dialysis or prediabetic individuals with impaired fasting glucose or impaired glucose tolerance by OGTT

- Male or female age = 18 years old and = 70 year old.

- Women who are not pregnant, lactating or planning a pregnancy during their participation in the clinical study.

- Willingness, ability and commitment to comply with the testing, procedure and follow-up outlined in this protocol including (but not limited to) frequency of clinic visits and use of pre-specified glucose monitoring devices.

- Willingness to abstain from swimming during their participation in the measurement phase.

- In the opinion of the investigator, absence of any physical limitations, addictive diseases, or underlying medical conditions (including mental health) that may preclude the patient from being a good study candidate.

- Written informed consent to participate in the study provided by the patient.

Exclusion Criteria:

- Poorly controlled diabetes mellitus with HbA1C >11%.

- Currently pregnant, as demonstrated by a positive pregnancy test at screening and on Day00 .

- Impaired hepatic function measured as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) = three times the upper reference limit.

- Any active acute or chronic disease or condition that, in the opinion of the investigator, might interfere with the performance of this study.

- Any active acute or chronic infectious disease that, in the opinion of the investigator, would pose an excessive risk to study staff.

- Current use or recent exposure to any medication that in the opinion of the investigator could have an influence on the patient's ability to participate in this study or on the performance of the test device.

- Extensive skin changes/diseases that preclude wearing the required number of devices on normal skin at the proposed application sites (e.g., extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis).

- Have a known allergy to medical-grade adhesives, or known hypersensitivity to any of the products used in the study.

- Known current or recent alcohol or drug abuse

- Blood donation of more than 500 ml within the last three months

- Currently participating in another investigational study protocol where the testing or results may interfere with study compliance, diagnostic results, or data collection.

- Has a MRI scan, CT scan, or diathermy scheduled during the proposed study participation.

- An identified protected vulnerable patient (including but not limited to those in detention, or a prisoner).

- Women of reproductive potential who are unwilling to adopt contraceptive measures during the study period

Study Design


Related Conditions & MeSH terms


Intervention

Device:
FiberSense sensor
The FiberSense system is a glucose-monitoring device indicated for continually recording interstitial fluid glucose levels in patients ages 18 and older with insulin dependent diabetes mellitus for the purpose of improving diabetes management.
Dexcom Sensor
Dexcom is a continuous glucose monitoring (CGM) system. The display device shows the glucose readings and the trend.

Locations

Country Name City State
Hong Kong The Chinese University of Hong Kong Sha Tin

Sponsors (1)

Lead Sponsor Collaborator
Lee's Pharmaceutical Limited

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary Blood glucose The primary endpoint is the proportion of FiberSense readings within =15% of the reference (YSI) reading for blood glucose levels >100 mg/dl, and the proportion of FiberSense readings within =15 mg/dl of the YSI reading for blood glucose levels =100 mg/dl, for paired samples taken during the in-clinic sessions. 28 days
Primary Adverse Events reporting 35 days
Secondary Mean Relatives Differences from YSI 28 days
Secondary Median Relatives Differences from YSI 28 days
Secondary Mean Absolute Relative Differences from YSI 28 days
Secondary Median Absolute Relative Differences from YSI 28 days
Secondary Hypoglycemia detection rates 28 days
Secondary Hyperglycemia detection rates 28 days
Secondary Accuracy of glucose rate of change of FiberSense sensor compared to glucose rate of change of YSI 28 days
Secondary Lag time between FiberSense readings and YSI results during induced glucose excursions 28 days
Secondary Agreement and accuracy relative to SMBG readings (same model to be used by all subjects) 28 days
Secondary Calibration stability 28 days
Secondary Sensor stability 28 days
Secondary Sensor life 28 days
Secondary User satisfaction questionnaire score 28 days
Secondary Blood maltose concentrations Measured in CAPD subjects during the V1 in-clinic session 28 days
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A